Table 2. The predictive values of related clinical parameters and risk score.

Variables		Patient n = 371	Univariate analysis		Multivariate analysis	P
			HR (95% CI)	P	HR (95% CI)
Sex	Female	170	1 (reference)
	Male	201	1.180 (0.761–1.831)	0.459
Age	<= 65 years	162	1 (reference)
	> 65 years	209	1.284 (0.816–2.022)	0.280
Disease stage	I	67	1 (reference)		1 (reference)
	II	146	2.187 (0.759–6.304)	0.147	1.225E4 (0.000–1.976E86)	0.922
	III	99	3.904 (1.354–11.257)	0.012	8.180E4 (0.000–1.328E87)	0.907
	IV	52	9.645 (3.351–27.758)	< 0.001	2.394E5 (0.000–3.875E87)	0.989
T stage	T1	10	1 (reference)
	T2	68	0.452 (0.087–2.352)	0.345
	T3	249	1.052 (0.256–4.332)	< 0.944
	T4	44	4.078 (0.937–17.747)	< 0.061
N stage	N0	227	1 (reference)		1 (reference)
	N1	82	1.827 (1.059–3.151)	0.030	0.624 (0.096–4.049)	0.621
	N2-N3	61	4.348 (2.577–7.337)	< 0.001	0.868 (0.136–5.555)	0.881
M stage	M0	269	1 (reference)
	M1	51	4.601 (2.773–7.636)	< 0.001
Lymphatic invasion	NO	211	1 (reference)		1 (reference)
	YES	120	1.960 (1.219–3.150)	0.005	0.380 (0.121–1.189)	0.096
Venous invasion	NO	248	1 (reference)		1 (reference)
	YES	74	2.490 (1.547–4.006)	< 0.001	1.331 (0.438–4.048)	0.614
Treatment outcome	CR+PR	123	1 (reference)
	SD+PD	29	7.320 (3.491–15.347)	<0.001
Radiotherapy	NO	308	1 (reference)
	YES	8	0.740 (0.102–5.355)	0.765
Neoplasm recurrence	NO	256	1 (reference)		1 (reference)
	YES	60	2.990 (1.855–4.819)	< 0.001	3.030 (1.234–7.440)	0.016
Residual tumor	R0	263	1 (reference)		1 (reference)
	R1+R2	20	3.953 (1.933–8.082)	< 0.001	1.660 (0.607–4.537)	0.323
Dimession	<=10 mm	137	1 (reference)
	> 10 mm	124	0.944 (0.537–1.659)	0.840
Risk score	Low	170	1 (reference)		1 (reference)
	High	201	2.948 (1.779 – 4.886)	< 0.001	9.389 (2.737–32.213)	<0.001

HR: hazard ratio; CI: confidence interval; SD: stable disease; PD: progressive disease; CR: complete response; PR: partial response.